Reaction
Upper Respiratory Tract Inflammation reporting signals
As of the last recalculation, Upper Respiratory Tract Inflammation appears in 1,190 FAERS reports alongside 36 co-occurring drug terms. The strongest observed disproportionality signal is CANAKINUMAB (PRR 36.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Canakinumab | 22 | 36.2 | 36.3 |
| Pitavastatin Calcium | 17 | 29.5 | 29.5 |
| Palivizumab | 22 | 25.5 | 25.5 |
| Tolvaptan | 18 | 22.0 | 22.0 |
| Magnesium Oxide | 50 | 21.8 | 21.8 |
| Febuxostat Tablets 40 Mg | 12 | 20.8 | 20.9 |
| Febuxostat Tablets 80 Mg | 12 | 20.8 | 20.9 |
| Misoprostol | 11 | 19.9 | 20.0 |
| Ketoprofen | 14 | 18.9 | 18.9 |
| Prednisolone | 168 | 18.8 | 18.8 |
| Prednisolone Oral | 168 | 18.8 | 18.8 |
| Prednisolone Oral Solution | 168 | 18.8 | 18.8 |
| Selexipag | 27 | 18.7 | 18.7 |
| Zonisamide | 15 | 17.9 | 18.0 |
| Tranexamic Acid | 9 | 17.8 | 17.8 |
| Indapamide | 18 | 17.8 | 17.8 |
| Lubiprostone | 8 | 14.9 | 14.9 |
| Romiplostim | 12 | 14.1 | 14.1 |
| Sirolimus | 10 | 13.1 | 13.1 |
| Febuxostat | 12 | 12.6 | 12.6 |
| Clarithromycin | 24 | 12.5 | 12.5 |
| Dexamethasone Sodium Phosphate | 7 | 12.1 | 12.1 |
| Desoximetasone | 11 | 10.2 | 10.2 |
| Oseltamivir Phosphate | 14 | 10.1 | 10.1 |
| Granisetron Hydrochloride | 6 | 10.1 | 10.1 |
| Vigabatrin | 8 | 9.7 | 9.7 |
| Ixazomib | 15 | 9.2 | 9.2 |
| Mepolizumab | 25 | 9.0 | 9.0 |
| Levocetirizine Dihydrochloride | 12 | 8.8 | 8.8 |
| Mirabegron | 19 | 8.7 | 8.7 |
| Eculizumab | 25 | 8.2 | 8.2 |
| Macitentan | 30 | 7.7 | 7.8 |
| Bendamustine Hydrochloride | 5 | 7.3 | 7.3 |
| Belimumab | 12 | 6.7 | 6.7 |
| Methoxy Polyethylene Glycol-Epoetin Beta | 4 | 6.4 | 6.4 |
| Emicizumab | 3 | 4.3 | 4.3 |